Blueprint Medicines News

Blueprint Medicines Analyst Ratings

BenzingaJun 7 13:13 ET

Blueprint Medicines Analyst Ratings

BenzingaMay 14 05:57 ET

Blueprint Medicines Analyst Ratings

BenzingaMay 6 11:16 ET

Blueprint Medicines Analyst Ratings

BenzingaMay 3 15:00 ET

JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125

BenzingaMay 3 15:02 ET

Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)

TipRanksMay 3 07:06 ET

Sell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth Factors

TipRanksMay 3 06:47 ET

Ayvakit's Sales Surge Supports Buy Rating and Increased Price Target for Blueprint Medicines

TipRanksMay 3 06:27 ET

Blueprint Medicines Analyst Ratings

BenzingaMay 3 05:49 ET

Buy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline Prospects

TipRanksMay 3 00:25 ET

Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating

MT NewswiresMay 2 10:56 ET

Blueprint Medicines Analyst Ratings

BenzingaMay 2 07:53 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)

TipRanksMay 1 03:41 ET

Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)

TipRanksApr 26 06:20 ET

Blueprint Medicines Analyst Ratings

BenzingaApr 26 05:33 ET

Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)

TipRanksApr 26 04:47 ET

Blueprint Medicines: Buy Rating Affirmed on BLU-808 Prospects and Strong Ayvakit Sales Forecast

TipRanksApr 25 20:05 ET

Blueprint Medicines Analyst Ratings

BenzingaApr 10 10:58 ET

Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook

TipRanksApr 9 16:25 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH)

TipRanksApr 5 06:40 ET